Explore This Treatment Program

Overview

Cystic fibrosis (CF) is a complex, inherited disease that causes a defect in the electrolyte transport system, leading to problems in the function of many organ systems such as the lungs and gastrointestinal tract. CF affects about 30,000 people in the United States. Although there is no cure yet, comprehensive care has led to improved prognoses for many individuals living with CF and research is providing new insights and new therapies.

The Pediatric Cystic Fibrosis Program at MassGeneral Hospital for Children (MGHfC) is a Cystic Fibrosis Foundation (CFF) accredited pediatric CF clinic committed to providing first-class, individualized care for each patient. We have an established multidisciplinary team to provide preventive care, active management of lung health, nutrition support and psychological support. Optimal treatment is accomplished through frequent outpatient visits with the CF care team, direct communication with families, and educational programs.

The Massachusetts General Hospital Cystic Fibrosis Center is comprised of the Pediatric CF Program and the Adult CF Program. Members of these care teams work closely to provide optimal care across all ages, with a fluid transition from the pediatric program to the adult program. For more information on the adult CF program, please visit the Adult Cystic Fibrosis Center page.

For families coping with a positive result from a CF newborn screening test, we offer a state-of-the-art system for CF diagnostic testing (sweat chloride testing), and our CF specialists will meet with you the same day to discuss the test results.

For sweat test appointments please call 617-724-0703 or 617-724-2992. Orders can be faxed to 617-724-2803 (ATTN: Sweat Test Laboratory)

Research & Clinical Trials

Cutting-Edge Clinical and Basic Research

MGHfC is a Cystic Fibrosis Foundation supported therapeutic development center and part of the nationwide therapeutic development network. Critical cutting-edge clinical research forms the basis of therapeutic advances, and our program is involved in most major clinical trials. Currently, we offer over 15 clinical therapeutic trials for CF patients, with therapeutic treatments targeting CFTR modulation (“correctors”), inflammation, and airway mucociliary clearance. If you are interested in participating in any of these clinical trials, please contact our research team at 617-726-3716 or mghfcclinicalresearch@partners.org or email our senior clinical research coordinator, Hanna Pinsky at hpinsky@mgh.harvard.edu.

To find a clinical trial that is right for you, go to the CFF Clinical Trial Finder.

Mass General has a strong history of leading the field in basic, translational and clinical research. CF-specific research programs at Mass General include groups focused on:

Additional Resources